<DOC>
	<DOCNO>NCT00646503</DOCNO>
	<brief_summary>This study explore efficacy safety Telbivudine fifth year treatment .</brief_summary>
	<brief_title>Prospective Exploratory Study Evaluate Safety Efficacy Telbivudine Fifth Year Treatment Chinese Patients With Compensated Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Inclusion criterion Patient complete Omnibus study available immediately rollover study without discontinuation study drug . Patient discontinue previous Omnibus study . Male female , adult patient CHB ( HBeAg positive HBeAg negative ) . Patient willing able provide write informed consent participate study . HBV DNA PCR undetectable recent 12 month . Exclusion criterion Pregnant breastfeeding , plan pregnant study period . Patient coinfected hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) , r HIV screen visit . Patient need antiHBV treatment combination ( addon therapy ) switch anti HBV treatment Telbivudine investigator 's discretion . Patient laboratory value abnormality physician think he/she may suitable continue Telbivudine treatment . Patient clinically significant concurrent severe unstable disease condition physicians think he/she may additional risk suitable participate study . Patient evidence renal insufficiency define patient require dialysis estimate creatinine clearance 50mL/min , estimate cockcroftGault formula . Patient currently abuse alcohol illicit drug . Patient enrol plan enroll another clinical trial investigational agent participate study . All treatment hepatitis B , include commercially available treatment indicate condition chronic hepatitis B investigate treat may activity HBV ( e.g. , ribavirin , famciclovir , ganciclovir , etc . ) Prolonged use systemic acyclovir famciclovir define episodic treatment agent period exceed 10 day every 3 month , chronic suppressive therapy . Systemic immunomodulators type . Systemic corticosteroid ( topical inhale corticosteroid permit ) . Herbal medication know cause hepatotoxicity ( e.g. , St. John 's Wart , Kava , Jin Bu Huan , Yuzhitang , germander , chaparral , shark cartilage , mistletoe , slim 10 , Lipokinetix , etc. ) . Patient follow laboratory value : Hemoglobin &lt; 9 g/dL menor &lt; 8 g/dL woman . Total WBC &lt; 1,500/mm3 Absolute neutrophil count ( ANC ) &lt; 1,000/mm3 Platelet count &lt; 30,000/mm3 Serum albumin &lt; 2.5g/dL Total bilirubin ≥4×ULN Serum creatinine &gt; 1.5×ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis B , Chronic</keyword>
	<keyword>Telbivudine</keyword>
	<keyword>Polymerase Chain reaction</keyword>
</DOC>